Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: | Immunology | Hepatology (Liver, Pancreatic, Gall Bladder) | Infections and Infectious Diseases | Vaccines
Search Medical Condition
Hepatitis Clinical Trials
A listing of Hepatitis medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Found (492) clinical trials
The REGENERATE Study (Research Study for Treatment of NASH (Non-Alcoholic Steato-Hepatitis)/Advanced Fatty-Liver Disease)
The purpose of this study is to find out how safe and effective OCA may be in delaying or preventing specific medical conditions or health related issues that can occur in patients with NASH and evidence of liver fibrosis. The investigational drug, OCA, is a modified (man-made) version of a ...
Chronic Hepatitis C Virus (HCV)
People with Hepatitis C Virus are asked to participate in a research study being conducted by Montefiore Medical Center.
Nonalcoholic Fatty Liver / Nonalcoholic steatohepatitis (NASH)
Nonalcoholic steatohepatitis (NASH) is an advanced form of fatty liver disease. It is caused by excess fat in the liver that leads to inflammation and tissue injury. People with type 2 diabetes, obesity, high cholesterol, insulin resistance, and high blood pressure may have NASH. ACRC Trials is conducting a research ...
The Immunologic Effects of HCV Therapy with Fixed Dose Combination Ledipasvir/Sofosbuvir (HARVONI) in HCV Genotype 1 Chronically Mono-infected Active and Former IDUs.
The body’s immune system usually becomes active when the body is fighting off an infection or disease. If an immune system is active for a long period of time, it may lead to problems such as heart, liver, and kidney disease. Many people who inject drugs are also infected with ...
Effects of Persistent Innate Immune Activation on Vaccine Efficacy
Hepatitis C is an infectious disease affecting primarily the liver, caused by the hepatitis C virus (HCV). HCV is spread primarily by blood-to-blood contact associated with intravenous drug use, poorly sterilized medical equipment and transfusions. An estimated 150-200 million people worldwide are infected with hepatitis C. The infection is often ...
A Phase 2, Multicenter, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Ledipasvir Fixed-Dose Combination + Ribavirin Administered in Subjects Infected with Chronic HCV who have Advanced Liver Disease or are Post-Liver Transplant
To explore the antiviral efficacy of combination therapy with sofosbuvir/ledipasvir fixed-dose combination ribavirin for 12 or 24 weeks in patients with advanced liver disease. Study designed with A cohort and B cohort.
Clinical trial to test a study drug in Patients with Chronic Hepatitis C
The purpose of this study is to evaluate the safety and effectiveness of an FDA-approved study drug as a sleep aid as compared to placebo (an inactive substance) in the treatment of insomnia associated with interferon-induced insomnia in patients with chronic hepatitis C (CHC). In addition, another purpose of this ...
Study for a new, investigational vaccine for Hepatitis B
This is a study for an investigational vaccine for Hepatitis B.
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment Naïve, HIV-1 and Hepatitis B Co-Infected Adults
The primary objective of this study is to evaluate the efficacy of fixed-dose combination (FDC) of bictegravir/emtricitabine/ tenofovir alafenamide (B/F/TAF) versus dolutegravir (DTG) + emtricitabine/tenofovir disoproxil fumarate (F/TDF) in HIV and hepatitis B virus (HBV) treatment naive, HIV-1 and HBV co-infected adults.
Sofosbuvir/Velpatasvir in Postpartum Women With Opioid Use Disorder and Chronic Hepatitis C Infection
Incorporating HCV treatment into opioid maintenance treatment program clinical protocols is an innovative health care delivery model that has been associated with improved HCV treatment uptake in non-pregnant, drug-using populations. This "medical home" approach would combine HCV and opioid maintenance treatment into one treatment regimen and incorporate the expertise of ...
